MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-09-05 · via Endpoints News

RNAi Biotech ADARx Files for IPO with Three Clinical-Stage Programs

ADARx Pharmaceuticals, a San Diego-based RNA interference company, has submitted an SEC filing to go public. The biotech, which has a collaboration with AbbVie, currently has three drug candidates in clinical development. It is seeking to ride the current momentum in the biotech IPO market.

Expanded Detail

EXPANDED:

ADARx Pharmaceuticals, based in San Diego, has taken the initial step toward becoming a publicly traded company by submitting a registration statement to the Securities and Exchange Commission. The firm specializes in RNA interference, a genetic silencing approach used to target disease-c

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at Endpoints News →
Related stories
NeuShen secures $80M to advance three clinical-stage brain therapies · Drug development
Electra Therapeutics files for Nasdaq listing to advance late-stage immunology candidate · Drug development
Arrowhead's RNAi candidate outperforms rival in late-stage triglyceride studies · Drug development
Biotech releases Phase 1 respiratory therapy results following premature poster exposure · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “AbbVie-allied ADARx aims for IPO with 3 drugs in the clinic.” Browse more stories.